Latanoprost / Timolol Farmalider (Timolol Maleate, Latanoprost)

• Latanoprost / Timolol is a combination ophthalmic therapy that targets intra‑ocular pressure regulation in glaucoma‑related conditions.
• Open‑angle glaucoma: reduces intra‑ocular pressure to prevent optic nerve damage.
• Ocular hypertension: lowers elevated eye pressure to reduce risk of progression to glaucoma.
• Secondary glaucoma (when indicated): provides additive pressure‑lowering effect alongside other treatments.

• Latanoprost, a prostaglandin F2α analogue, increases uveoscleral outflow of aqueous humor, while Timolol Maleate, a non‑selective beta‑adrenergic blocker, decreases aqueous humor production by inhibiting beta‑receptors in the ciliary body. The combined actions result in a synergistic reduction of intra‑ocular pressure.

Adverse reactions may occur with ocular use of the combination.

Common Side Effects

• Eye irritation or burning sensation
• Transient blurred vision
• Conjunctival hyperemia (red eye)
• Dry eye or foreign‑body sensation
• Increased eyelash growth
• Mild itching or discomfort

Serious or Rare Side Effects

• Severe allergic reaction (e.g., angio‑edema, anaphylaxis)
• Sudden loss of vision or acute ocular pain
• Worsening of glaucoma due to hypotony
• Systemic bronchospasm or asthma exacerbation
• Bradycardia or heart block in susceptible patients
• Chest pain or signs of myocardial ischemia

• Before initiating therapy, clinicians should evaluate patient‑specific risk factors and follow safe handling guidelines.
• Assess cardiovascular status: avoid in patients with severe asthma, COPD, bradycardia or heart block.
• Monitor intra‑ocular pressure: schedule regular ophthalmic examinations.
• Check beta‑blocker contraindications: review concomitant systemic beta‑blocker use.
• Avoid concurrent prostaglandin analogs: prevent excessive pressure reduction.
• Pregnancy and lactation: use only if clearly needed after risk‑benefit assessment.
• Store at room temperature: keep bottle in original packaging, protect from light and moisture.

Latanoprost / Timolol may interact with other systemic or ocular agents; awareness of interaction severity guides clinical decisions.

Major Interactions (Avoid)

• Non‑selective systemic beta‑blockers: additive bradycardia and hypotension.
• Other ocular prostaglandin analogues: risk of excessive intra‑ocular pressure lowering (hypotony).
• Systemic carbonic anhydrase inhibitors: may potentiate hypotensive effects.
• Sympathomimetic agents (e.g., epinephrine eye drops): can diminish timolol efficacy.

Moderate Interactions (Monitor Closely)

• Topical ocular anesthetics: may increase ocular irritation.
• Systemic antihypertensives: monitor blood pressure for additive lowering.
• Corticosteroid eye drops: possible reduction in pressure‑lowering effect.
• Anticholinergic eye preparations: watch for compounded ocular side effects.